Longitudinal variation of serum periostin levels in adults with stable asthma - 27/09/17
Doi : 10.1016/j.jaci.2016.11.041
Ruth Semprini, MB BS a, b 
, Rachel Caswell-Smith, MBChB a, b, James Fingleton, PhD a, Cecile Holweg, PhD c, John Matthews, PhD c, Mark Weatherall, MBChB d, Richard Beasley, DSc a, b, Irene Braithwaite, PhD a, b
on behalf of the
, Rachel Caswell-Smith, MBChB a, b, James Fingleton, PhD a, Cecile Holweg, PhD c, John Matthews, PhD c, Mark Weatherall, MBChB d, Richard Beasley, DSc a, b, Irene Braithwaite, PhD a, bon behalf of the
Periostin Study Team
a Medical Research Institute of New Zealand, Wellington, New Zealand
b Faculty of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
c OMNI - Biomarker Development, Genentech, South San Francisco, Calif
d Department of Medicine, University of Otago, Dunedin, New Zealand
| Supported by Genentech. This study was approved by the New Zealand Health and Disability Ethics committee (13/NTB/185). This study was prospectively registered with Australia and New Zealand Clinical Trials Register (ACTRN12614000235606). |
|
| Disclosure of potential conflict of interest: R. Semprini, R. Caswell-Smith, J. Fingleton, and I. Braithwaite have all received grants from Genentech. C. Holweg is an employee of Genentech, a member of the Roche group. J. Matthews is employed by Genentech, a member of the Roche group, and is a named inventor on a pending patent application assigned to his employer relating to subject matter in the manuscript. R. Beasley reports grants from Genentech during the conduct of the study and personal fees from the Health Research Council of New Zealand, GlaxoSmithKline, AstraZeneca, and Novartis and grants from AstraZeneca, Chiesi, Cephalon, Genentech, Novartis, Sanofi Aventis, outside the submitted work. M. Weatherall declares that he has no conflicts of interest. |
© 2017
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 5
P. 1687 - mai 2017 Retour au numéro
Article précédent
- Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
- Federico Alberici, Rona M. Smith, Mariana Fonseca, Lisa C. Willcocks, Rachel B. Jones, Julia U. Holle, Stefan Wieczorek, Thomas Neumann, Davide Martorana, Gina Gregorini, Renato A. Sinico, Annette Bruchfeld, Iva Gunnarsson, Sophie Ohlsson, Bo Baslund, Vladimir Tesar, Zdenka Hruskova, Maria C. Cid, Augusto Vaglio, Paul A. Lyons, Kenneth G.C. Smith, David R.W. Jayne
- Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency
- Christina Gavino, Marija Landekic, Jibin Zeng, Ning Wu, Sungmi Jung, Ming-Chao Zhong, Alexis Cohen-Blanchet, Mélanie Langelier, Odile Neyret, Duncan Lejtenyi, Claudia Rochefort, Judith Cotton-Montpetit, Christine McCusker, Bruce Mazer, André Veillette, Donald C. Vinh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?